The Demand for Internal Auditors following Accounting and Operational Failures
The Accounting Review · 01.11.2023 · 98 (7) · 185-210
DOI: 10.2308/tar-2021-0484 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Accounting Review, online erschienen am 23.10.2023. Verfasst von Matthew S. Ege und 2 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Using a comprehensive database of U.S. internal auditor job postings, we find that firms are about 10 percent more likely to post an internal auditor job after the revelation of accounting and operational failures. Also, the demand for internal auditors is stronger when a failure is more severe. Among firms posting internal auditor jobs, firms demand higher-quality internal auditors in response to a failure compared with when there has not been a recent failure. We find evidence of internal audit demand spillovers through connected directors, which helps mitigate concerns that the primary results are due to replacing internal auditors that recently left or due to endogenous links between hiring internal auditors and failure revelations. Overall, our evidence suggests that firms demand internal auditors to help ensure high-quality financial reporting and effective operations. JEL Classifications: G34, J23, M41, M42.
Zitieren
APA
Ege, M. S., Kim, Y. H., & Wang, D. (2023). The Demand for Internal Auditors following Accounting and Operational Failures. The Accounting Review, 98(7), 185-210. https://doi.org/10.2308/tar-2021-0484
Vancouver
Ege MS, Kim YH, Wang D. The Demand for Internal Auditors following Accounting and Operational Failures. The Accounting Review. 2023;98(7):185-210. doi:10.2308/tar-2021-0484
BibTeX
@article{Ege2023,
author = {Ege, Matthew S. and Kim, Young Hoon and Wang, Dechun},
title = {The Demand for Internal Auditors following Accounting and Operational Failures},
journal = {The Accounting Review},
year = {2023},
volume = {98},
number = {7},
pages = {185--210},
doi = {10.2308/tar-2021-0484}
}
EUVIMED